1,2-bis(bromomethyl)-4-(trifluoromethyl)benzene | 74815-76-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-bis(bromomethyl)-4-(trifluoromethyl)benzene
• CAS: 74815-76-2
• 化学式: C₉H₇Br₂F₃
• 分子量: 331.958
• InChiKey: YPTYLQNUERVVHH-UHFFFAOYSA-N

物化性质

• 沸点：
  269.5±35.0 °C(Predicted)
• 密度：
  1.824±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-bis(bromomethyl)-4-(trifluoromethyl)benzene 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 12.0h， 生成 2-(3-phenylprop-2-yn-1-yl)-5-(trifluoromethyl)isoindoline
  参考文献：
  名称：

  Gold-Catalyzed [1,5]-Hydride Shift onto Unactivated Alkynes To Trigger an Intermolecular Diels–Alder Reaction

  摘要：

  A [1,5]-hydride shift of sp(3) C-H onto an unactivated carbon carbon triple bond catalyzed by a gold(I) complex enabled N-propargylisoindolines to be latent dienes and therefore triggered an intermolecular Diels-Alder reaction with dienophiles. This protocol provides an atom-economical and straightforward approach to access a wide range of polycyclic skeletons in high yields and with excellent diastereoselectivities from easily accessible molecules.

  DOI：

  10.1021/ol5017355
• 作为产物：
  描述：

  3,4-二甲基三氟甲苯 在 过氧化苯甲酰 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 反应 8.0h， 以52%的产率得到1,2-bis(bromomethyl)-4-(trifluoromethyl)benzene
  参考文献：
  名称：

  WO2006/122200

  摘要：

  公开号：

文献信息

• COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
  申请人：COGNITION THERAPEUTICS, INC.

  公开号：US20170197977A9

  公开（公告）日：2017-07-13

  This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.

  这项发明涉及与sigma-2受体结合的新型二芳胺化合物，包括这种化合物的药物组合物，以及用于抑制或恢复神经元细胞中突触丢失，调节神经元细胞中膜运输变化，并用于治疗认知衰退和神经退行性疾病和障碍的方法。
• [EN] PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS<br/>[FR] DÉRIVÉS DE PYRANE EN TANT QU'INHIBITEURS DE CYP11A1 (CYTOCHROME P450 MONOOXYGÉNASE 11A1)
  申请人：ORION CORP

  公开号：WO2018115591A1

  公开（公告）日：2018-06-28

  Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroidreceptor, particularly androgen receptor,dependent diseases and conditions, such asprostate cancer.

  公式(I)的化合物，其中R1、R2、R3、R4、R5、R23、R24、L、A和B如权利要求1中定义，或其药用可接受的盐被披露。公式(I)的化合物具有作为细胞色素P450单加氧酶11A1（CYP11A1）抑制剂的使用价值。这些化合物作为药物用于治疗激素受体，尤其是雄激素受体相关的疾病和状况，如前列腺癌。
• HETEROARYL-PYRAZOLE DERIVATIVE
  申请人：Nakamura Toshio

  公开号：US20130137865A1

  公开（公告）日：2013-05-30

  A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

  公式[I]所代表的化合物及其药学上可接受的盐是一种新颖的化合物及其药学上可接受的盐，对II类代谢型谷氨酸（mGlu）受体具有拮抗活性，并且作为一种新型预防或治疗剂对情绪障碍（抑郁症、双相情感障碍等）、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧障碍、急性应激障碍等）、精神分裂症、阿尔茨海默病、认知障碍、痴呆、药物依赖、抽搐、颤抖、疼痛、睡眠障碍等疾病具有有效性。
• ETHINYL-PYRAZOLE DERIVATIVE
  申请人：Nakamura Toshio

  公开号：US20130123500A1

  公开（公告）日：2013-05-16

  Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

  提供的是一种由化学式[I]表示的新化合物，或者其在药学上可接受的盐，具有对抗第二组代谢型谷氨酸（m-Glu）受体的拮抗活性。该化合物或其药学上可接受的盐可用作预防或治疗剂，用于诸如新的情绪障碍（抑郁和双相障碍）、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧症和急性应激障碍）、精神分裂症、阿尔茨海默病、认知功能障碍、痴呆、药物依赖、癫痫、震颤、疼痛、睡眠障碍等疾病。
• Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
  申请人：Goble D. Stephen

  公开号：US20060178363A1

  公开（公告）日：2006-08-10

  The present invention is directed to compounds of the formula (1) Wherein A, B, D, X, Y, n, R 1 , R 3 , R 4 , R 5 , R 15 , R 16 , R 17 , R 18 and the dashed line are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及式（1）的化合物，其中A、B、D、X、Y、n、R1、R3、R4、R5、R15、R16、R17、R18和虚线所定义的内容，这些化合物可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。